Vaginal DHEA is a prescription insert that delivers a small dose of the hormone precursor DHEA (dehydroepiandrosterone) directly into the vaginal tissue, where it converts into estrogens and androgens locally. It is FDA-approved under the brand name Intrarosa to treat moderate to severe pain during sex caused by vaginal changes after menopause. The standard dose is a 6.5 mg insert used once daily at bedtime.
How Vaginal DHEA Works
DHEA is a naturally occurring hormone your body produces in large quantities during your reproductive years. After menopause, levels drop significantly. Vaginal tissue contains specialized enzymes that can take DHEA and convert it into small amounts of estrogen and testosterone right where it’s needed. This localized conversion process is called intracrine activity: the hormones are made and used inside the same cells, rather than circulating throughout your body.
This is the key distinction from taking a hormone pill. Because the conversion happens within the vaginal cells themselves, systemic hormone levels stay very low. In clinical measurements, women using vaginal DHEA showed hormone concentrations that remained in the lowest half or lowest quartile of the normal postmenopausal range. The uterine lining (endometrium) lacks the enzymes needed to convert DHEA into estrogen, which is why the treatment stimulates vaginal tissue without affecting the uterus.
What It Treats
Vaginal DHEA targets a cluster of symptoms that develop when vaginal tissue thins and loses moisture after menopause, sometimes called vulvovaginal atrophy or genitourinary syndrome of menopause. The most prominent symptom it addresses is dyspareunia, which is pain during sexual intercourse. It also improves vaginal dryness and overall tissue health.
In a 12-week clinical trial of the 6.5 mg dose, vaginal pH dropped by 0.66 units more than placebo, which reflects a shift back toward the slightly acidic environment of premenopausal tissue. The percentage of mature, healthy surface cells increased significantly, while the immature cells that indicate thinning tissue decreased by nearly 28% compared to placebo. Pain during sex dropped by 1.42 severity score units from baseline. All four of these endpoints reached high statistical significance.
How It Compares to Vaginal Estrogen
Vaginal estrogen creams and tablets have been used for decades to treat the same symptoms. Head-to-head comparison data suggest that 6.5 mg of vaginal DHEA is at least as effective as low-dose conjugated estrogen (0.3 mg) or ultra-low-dose estradiol (10 mcg) for relieving vulvovaginal atrophy symptoms.
The practical difference is the mechanism. Vaginal estrogen delivers estrogen directly. Vaginal DHEA delivers a precursor and lets your cells decide what to make from it, which includes both estrogen and androgens. Androgens play their own role in vaginal tissue health, contributing to moisture, elasticity, and nerve sensitivity. For women who prefer to avoid direct estrogen exposure, even at low local doses, vaginal DHEA offers an alternative pathway to the same outcome.
What to Expect When Using It
The insert is a small suppository you place in the vagina at bedtime using an applicator. It dissolves overnight. The standard regimen is one insert every night.
Improvements in tissue health are measurable within 12 weeks in clinical trials, and that timeline is a reasonable expectation for noticeable symptom relief. Vaginal cell maturation improved in 86% to 100% of women using DHEA over 12 weeks in one study, compared to 64% with a plain moisturizer alone. pH levels also dropped more in the DHEA groups, though the differences between DHEA and moisturizer were modest in absolute terms.
Side Effects
Vaginal DHEA is generally well tolerated. The most common side effect in clinical trials was vaginal discharge, reported by about 14% of women. Abnormal Pap smear results occurred in about 2% of participants, likely reflecting the increased cell maturation that the treatment is designed to produce rather than a harmful change.
Because DHEA converts partly into androgens, some women may notice androgen-related effects. In one study of cancer survivors using vaginal DHEA, voice changes and headaches were reported at rates statistically higher than with a plain moisturizer. These are uncommon but worth being aware of.
For Women With a Cancer History
This is an area where the evidence is still limited. The FDA approval of Intrarosa was based on studies of women with natural or surgically induced menopause, not cancer survivors. Women taking aromatase inhibitors experience extreme estrogen suppression, and the effects of adding even a small local source of hormone precursor in that context are not fully understood.
Early research in cancer survivors has shown that vaginal DHEA does raise hormone levels, though they remain within the low postmenopausal range. Whether that small increase matters for women with hormone-sensitive cancers is an open question. The decision to use vaginal DHEA in this population involves weighing the significant quality-of-life burden of vaginal symptoms against the theoretical risk of even minimal hormone exposure.